HUP0203801A2 - Eljárás rekombináns adenovírusok előállítására és adenovírus-könyvtárak - Google Patents

Eljárás rekombináns adenovírusok előállítására és adenovírus-könyvtárak

Info

Publication number
HUP0203801A2
HUP0203801A2 HU0203801A HUP0203801A HUP0203801A2 HU P0203801 A2 HUP0203801 A2 HU P0203801A2 HU 0203801 A HU0203801 A HU 0203801A HU P0203801 A HUP0203801 A HU P0203801A HU P0203801 A2 HUP0203801 A2 HU P0203801A2
Authority
HU
Hungary
Prior art keywords
adenovirus
banks
preparation
recombinant adenoviruses
adenoviruses
Prior art date
Application number
HU0203801A
Other languages
English (en)
Inventor
Jean-Jacques Robert
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0203801A2 publication Critical patent/HUP0203801A2/hu
Publication of HUP0203801A3 publication Critical patent/HUP0203801A3/hu
Publication of HU228933B1 publication Critical patent/HU228933B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

A találmány tárgyát készítmények és rekombináns adenovírusokelőállítására szolgáló eljárások képezik. Az előállítottadenovírusokat gének sejtekbe való bevitelére, és/vagy sejtekben valóin vitro, ex vivo vagy in vivo expresszálására, vagy funkcionálisgenomi genetikában lehet alkalmazni. A találmány tárgyát képezikkülönösen olyan eljárások, amelyek különösen hatékonyak adenovírus-könyvtárak előállítására, és a könyvtárak alkalmazásai funkcionálisgenomi genetikában. A találmány tárgyát képezik plazmidok, amelyeketilyen adenovírusok előállítására lehet alkalmazni, sejtek, amelyekilyen plazmidokat tartalmaznak, és reagenskészletek, amelyek ezeket aplazmidokat, sejteket és/vagy adenovírus-könyvtárakat tartalmazzák. Ó
HU0203801A 1999-10-07 2000-10-05 Recombinant adenoviruses preparation and adenovirus banks HU228933B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9912521A FR2799472B1 (fr) 1999-10-07 1999-10-07 Preparation d'adenovirus recombinants et de banques adenovirales
US16835699P 1999-12-01 1999-12-01
PCT/FR2000/002774 WO2001025463A1 (fr) 1999-10-07 2000-10-05 Preparation d'adenovirus recombinants et de banques adenovirales

Publications (3)

Publication Number Publication Date
HUP0203801A2 true HUP0203801A2 (hu) 2003-03-28
HUP0203801A3 HUP0203801A3 (en) 2005-01-28
HU228933B1 HU228933B1 (en) 2013-06-28

Family

ID=26235132

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203801A HU228933B1 (en) 1999-10-07 2000-10-05 Recombinant adenoviruses preparation and adenovirus banks

Country Status (22)

Country Link
US (1) US8263395B2 (hu)
EP (1) EP1224310B1 (hu)
JP (1) JP5260815B2 (hu)
KR (1) KR100928105B1 (hu)
CN (1) CN1384885B (hu)
AT (1) ATE355385T1 (hu)
AU (1) AU785431B2 (hu)
BR (1) BR0014489B1 (hu)
CA (1) CA2383225C (hu)
CZ (1) CZ302282B6 (hu)
DE (1) DE60033679T2 (hu)
DK (1) DK1224310T3 (hu)
FR (1) FR2799472B1 (hu)
HK (1) HK1050211B (hu)
HU (1) HU228933B1 (hu)
IL (2) IL148493A0 (hu)
MX (1) MXPA02003247A (hu)
NO (1) NO330916B1 (hu)
NZ (1) NZ518763A (hu)
PL (1) PL210590B1 (hu)
WO (1) WO2001025463A1 (hu)
ZA (1) ZA200202481B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234980A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
EP2471909A1 (en) * 2010-12-30 2012-07-04 SIRION BIOTECH GmbH Nucleic acid molecules for generating adenoviral vectors
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) * 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2705363B1 (fr) 1993-05-13 1995-08-11 Clecim Sa Procédé de fusion de ferraille dans un four électrique et installation pour la mise en Óoeuvre du procédé.
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2724945B1 (fr) * 1994-09-27 1996-12-27 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
AU724922B2 (en) * 1995-06-07 2000-10-05 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
FR2755975B1 (fr) 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
US5846812A (en) * 1996-11-22 1998-12-08 Pioneer Hi-Bred International, Inc. Zearalenone detoxification compositions and methods
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6844270B2 (en) * 2000-11-26 2005-01-18 Shipley Company, L.L.C. Polymers and photoresist compositions for short wavelength imaging
SE523617C2 (sv) * 2001-10-01 2004-05-04 Sandvik Ab Skär för spånavskiljande bearbetning försedd med spånbrytande geometri
JP4308485B2 (ja) * 2002-07-08 2009-08-05 パナソニック株式会社 容量素子の製造方法
US6856551B2 (en) * 2003-02-06 2005-02-15 Sandisk Corporation System and method for programming cells in non-volatile integrated memory devices

Also Published As

Publication number Publication date
AU785431B2 (en) 2007-05-31
DE60033679T2 (de) 2007-11-15
HU228933B1 (en) 2013-06-28
BR0014489A (pt) 2002-06-04
US20090149349A1 (en) 2009-06-11
KR100928105B1 (ko) 2009-11-24
CA2383225A1 (fr) 2001-04-12
JP5260815B2 (ja) 2013-08-14
KR20020057969A (ko) 2002-07-12
IL148493A (en) 2010-04-15
CN1384885B (zh) 2011-06-22
BR0014489B1 (pt) 2013-05-21
AU7794700A (en) 2001-05-10
US8263395B2 (en) 2012-09-11
DE60033679D1 (de) 2007-04-12
EP1224310A1 (fr) 2002-07-24
WO2001025463A1 (fr) 2001-04-12
FR2799472A1 (fr) 2001-04-13
NZ518763A (en) 2005-01-28
CZ20021215A3 (cs) 2002-08-14
HK1050211B (zh) 2008-01-25
ZA200202481B (en) 2003-09-23
ATE355385T1 (de) 2006-03-15
IL148493A0 (en) 2002-09-12
CN1384885A (zh) 2002-12-11
FR2799472B1 (fr) 2004-07-16
PL354099A1 (en) 2003-12-29
JP2003512823A (ja) 2003-04-08
CZ302282B6 (cs) 2011-02-02
DK1224310T3 (da) 2007-07-02
MXPA02003247A (es) 2002-09-30
HUP0203801A3 (en) 2005-01-28
CA2383225C (fr) 2011-12-13
NO330916B1 (no) 2011-08-15
NO20021634L (no) 2002-06-04
HK1050211A1 (en) 2003-06-13
PL210590B1 (pl) 2012-02-29
EP1224310B1 (fr) 2007-02-28
NO20021634D0 (no) 2002-04-05

Similar Documents

Publication Publication Date Title
HUP0003331A2 (hu) Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
ZA200405388B (en) Binding proteins as biosensors
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
EP1458760A4 (en) BINDING PROTEINS TRACING AS BIOCAPTERS
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
HUP0203387A2 (hu) Permanens amniocita eredetű sejtvonal, előállítása és alkalmazása géntranszfer vektorok előállítására
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
AP9901654A0 (en) Gene sequencer and methods.
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
ATE345819T1 (de) Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
ATE386130T1 (de) Adenovirale vektoren für die gentherapie
HUP0203801A2 (hu) Eljárás rekombináns adenovírusok előállítására és adenovírus-könyvtárak
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
AU2092700A (en) Novel potassium channels and genes encoding these potassium channels
WO2001036679A3 (en) METHODS FOR GENERATING SINGLE STRANDED cDNA FRAGMENTS
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
YU63702A (sh) Novo antitelo sa specifičnošću za rak debelog creva
GB2385054B (en) Host cells obtained by introducing and expressing VHL gene in cancer cells or embryonic stem cells
HUP0203164A2 (hu) Koleszterin-metabolizmussal kapcsolatos betegségekben érintett gének expressziós termékei

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETK, HU